Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity
Repeat expansion mutations in the C9ORF72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Repeat-associated non-AUG translation of this expansion produces dipeptide repeat proteins (DRPs). The arginine containing DRPs, polyGR and polyP...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2020-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_52c48b9db7fc4bd5941fbfec7788cf7a | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Alan S. Premasiri |e author |
| 700 | 1 | 0 | |a Anna L. Gill |e author |
| 700 | 1 | 0 | |a Fernando G. Vieira |e author |
| 245 | 0 | 0 | |a Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity |
| 260 | |b Frontiers Media S.A., |c 2020-09-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2020.569661 | ||
| 520 | |a Repeat expansion mutations in the C9ORF72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Repeat-associated non-AUG translation of this expansion produces dipeptide repeat proteins (DRPs). The arginine containing DRPs, polyGR and polyPR, are consistently reported to be the most toxic. Here we demonstrated that small molecule inhibition of type I protein arginine methyltransferases (PRMT) protects against polyGR and polyPR toxicity. Furthermore, our findings suggest that asymmetric dimethylation of polyGR and polyPR by Type I PRMTs plays important roles in their cytotoxicity. | ||
| 546 | |a EN | ||
| 690 | |a ALS (Amyotrophic lateral sclerosis) | ||
| 690 | |a FTD (Fronto-Temporal Dementia) | ||
| 690 | |a C9ORF72 DPRs | ||
| 690 | |a arginine methylation | ||
| 690 | |a protein arginine methyl transferase | ||
| 690 | |a glycine-arginine | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 11 (2020) | |
| 787 | 0 | |n https://www.frontiersin.org/article/10.3389/fphar.2020.569661/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/52c48b9db7fc4bd5941fbfec7788cf7a |z Connect to this object online. |